MARKET

XERS

XERS

Xeris Pharmaceuticals
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.40
-0.05
-0.92%
Closed 19:51 03/01 EST
OPEN
5.58
PREV CLOSE
5.45
HIGH
5.80
LOW
5.40
VOLUME
1.77M
TURNOVER
--
52 WEEK HIGH
7.94
52 WEEK LOW
1.420
MARKET CAP
264.47M
P/E (TTM)
-1.7441
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
Most Food and Drug Administration decisions scheduled for February were positive, and more importantly five new molecular entities passed FDA muster.
Benzinga · 1d ago
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on February 24, 2021, the Co...
BusinessWire · 3d ago
Xeris Pharmaceuticals (XERS) Receives a Buy from Mizuho Securities
Mizuho Securities analyst Difei Yang maintained a Buy rating on Xeris Pharmaceuticals (XERS) today and set a price target of $14.00. The company's shares
SmarterAnalyst · 3d ago
Don't Just Sit There, Work Those Trades
You have the power to keep working to adjust your position size so that when a trade does work as hoped, you can maximize your gains....XERS
TheStreet.com · 02/20 10:00
Mizuho Securities Maintains a Buy Rating on Xeris Pharmaceuticals (XERS)
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Xeris Pharmaceuticals (XERS), with a price target of $14.00. The
SmarterAnalyst · 02/19 13:25
Xeris Pharmaceuticals to Webcast Upcoming Investor Conference Presentations
Business Wire · 02/18 13:00
Xeris Pharmaceuticals (XERS) Gets a Buy Rating from Mizuho Securities
Mizuho Securities analyst Difei Yang maintained a Buy rating on Xeris Pharmaceuticals (XERS) today and set a price target of $14.00. The company's shares
SmarterAnalyst · 02/12 13:46
Thinking about buying stock in Artelo Biosciences, Xeris Pharmaceuticals, Inovio Pharmaceuticals, Novan, or Fisker?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARTL, XERS, INO, NOVN, and FSR.
PR Newswire - PRF · 02/12 13:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XERS. Analyze the recent business situations of Xeris Pharmaceuticals through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XERS stock price target is 11.00 with a high estimate of 14.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 150
Institutional Holdings: 27.24M
% Owned: 55.61%
Shares Outstanding: 48.98M
TypeInstitutionsShares
Increased
36
1.42M
New
36
144.84K
Decreased
24
1.18M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.13%
Pharmaceuticals & Medical Research
+1.38%
Key Executives
Chairman/Chief Executive Officer/Director
Paul Edick
Chairman/President/Chief Executive Officer/Director
paul Edick
President/Chief Operating Officer
John Shannon
Co-Founder/Chief Scientific Officer
Steven Prestrelski
Chief Financial Officer
Barry Deutsch
Senior Vice President/General Counsel/Secretary
Beth Hecht
Senior Vice President
Kenneth Johnson
Lead Director/Independent Director
John Schmid
Independent Director
BJ Bormann
Independent Director
Dawn Halkuff
Independent Director
Marla Persky
Independent Director
Jeffrey Sherman
  • Dividends
  • Splits
  • Insider Activity
No Data
About XERS
Xeris Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing injectable and infusible drug formulations. It uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products. Its formulation technologies allow for the subcutaneous (SC) and intramuscular (IM) delivery of formulations of peptides, proteins, antibodies and small molecules using commercially-available syringes, auto-injectors, multi-dose pens and infusion pumps. The Company is developing its lead product candidate, the Glucagon Rescue Pen, for the treatment of severe hypoglycemia in people with diabetes. It is also developing treatments for post-bariatric hypoglycemia, congenital hyperinsulinism, hypoglycemia-associated autonomic failure and exercise-induced hypoglycemia. Its Glucagon Rescue Pen offers a stable glucagon that is designed to be administered subcutaneously in a simple two-step process.

Webull offers kinds of Xeris Pharmaceuticals Inc stock information, including NASDAQ:XERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XERS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XERS stock methods without spending real money on the virtual paper trading platform.